{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:27:38Z","timestamp":1792286858549,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","journals.elsevierhealth.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jiph.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T14:41:17Z","timestamp":1520520077000},"page":"727-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia"],"prefix":"10.1016","volume":"11","author":[{"given":"Marguerite L.","family":"Monogue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Ortwine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Eljaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita P.","family":"Bhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"March","key":"10.1016\/j.jiph.2018.02.004_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10096-015-2566-8","article-title":"Staphylococcus aureus bacteremic pneumonia","volume":"35","author":"De la calle","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"April","key":"10.1016\/j.jiph.2018.02.004_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/sur.2015.055","article-title":"Epidemiology of Staphylococcus aureus surgical site infections","volume":"17","author":"Marimuthu","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jiph.2018.02.004_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiph.2018.02.004_bib0020","series-title":"Active bacterial core surveillance report, emerging infections program network, methicillin-resistant Staphylococcus aureus","author":"Centers for Disease Control and Prevention","year":"2012"},{"issue":"October","key":"10.1016\/j.jiph.2018.02.004_bib0025","first-page":"380","article-title":"National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System","volume":"24","year":"1996","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiph.2018.02.004_bib0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"Van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"44","key":"10.1016\/j.jiph.2018.02.004_bib0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"15","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2018.02.004_bib0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jiph.2018.02.004_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"October (15)","key":"10.1016\/j.jiph.2018.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jiph.2018.02.004_bib0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/msb.2012.49","article-title":"The inoculum effect and band-pass bacterial response to periodic antibiotic treatment","volume":"8","author":"Tan","year":"2012","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.jiph.2018.02.004_bib0060","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.36.2.440","article-title":"Characterization of four beta-lactamases produced by Staphylococcus aureus","volume":"36","author":"Zygmunt","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2018.02.004_bib0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiph.2018.02.004_bib0075","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2018.02.004_bib0085","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1086\/339072","article-title":"The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents","volume":"34","author":"Powers","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2018.02.004_bib0095","first-page":"1","article-title":"Safety and efficacy of cefazolin sodium in the management of bacterial infection and in surgical prophylaxis","author":"Kusaba","year":"2009","journal-title":"Clin Med: Therap"},{"issue":"December (2)","key":"10.1016\/j.jiph.2018.02.004_bib0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40121-014-0049-3","article-title":"Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI)","volume":"3","author":"So","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2018.02.004_bib0105","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0110","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0115","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.04677-14","article-title":"Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"59","author":"Rao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2018.02.004_bib0125","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ncpneph0561","article-title":"Four cases of nafcillin-associated acute interstitial nephritis in one institution","volume":"3","author":"Hoppes","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jiph.2018.02.004_bib0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","article-title":"Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome","volume":"34","author":"Chong","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2018.02.004_bib0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and B-lactamase type on MSSA bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jiph.2018.02.004_bib0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2018.02.004_bib0145","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection: an observational study in a California tertiary medical center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2018.02.004_bib0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: A nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034118300297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034118300297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T15:30:18Z","timestamp":1535383818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034118300297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1876034118300297"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2018.02.004","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}